Madam Chair, an after-the-fact assessment of the Bell MTS transaction hasn't taken place. I can indicate that quite clearly. We are monitoring the compliance with the consent agreement.
I should say, sir, that we simply don't have the resources to conduct after-the-fact assessments of our merger remedies. The resources we have are going full out on current mergers, which we are tasked with reviewing under the law.
Second, we don't have powers in the Competition Act to compel the necessary information and data from parties in the marketplace in order to properly assess the effectiveness of a prior remedy. I can tell you, sir, that internally we would like to set up what we call a “remedies unit”, where we would have a centre of expertise inside the organization that monitors consent agreements, goes back and looks at them for their effectiveness and advises us on future agreements, but we simply don't have the human or financial resources to set up that remedies unit at this time.